The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as ...
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates ...
I don’t like established science,” ACIP chairperson Kirk Milhoan said in an interview on the Why Should I Trust You? podcast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback